WHI-P154 is a novel, potent and selective JAK3 (Janus kinase) inhibitor with potential antitumor activity.

AG-1557 is a novel and potent inhibitor of epidermal growth factor receptor tyrosine (EGFR) kinase.

Allitinib (formerly also known as AST1306; AST-1306) is a novel, potent, selective and covalent / irreversible inhibitor of EGFR and ErbB2 with potential antitumor activity.

Neratinib maleate, the maleate salt of neratinib (HKI-272; PB-272; Nerlynx), is an orally bioavailable HER2 and EGFR inhibitor approved by FDA in 2017 to reduce the risk of breast cancer returning.

JBJ-04-125-02 HCL is a novel, highly potent, mutant-specific, allosteric and orally bioavailable EGFR inhibitor with an IC50 of 0.26 nM for EGFRL858R/T790M.

Sapitinib (formerly AZD8931; AZD-8931) is an orally bioactive, reversible and ATP competitive inhibitor of multiple kinases including EGFR, ErbB2/3 with potential antitumor activity.

Almonertinib (HS10296) is a novel, potent, orally bioavailable, 3rd-generation irreversible inhibitor of the epidermal growth factor receptor (EGFR) mutant form T790M, with potential antineoplastic activity.

CNX-2006 (CNX2006), a CO-1686 analog, is a covalent / irreversible and mutant-selective EGFR inhibitor with potential antitumor activity.

Erlotinib HCl (formerly OSI-744, OSI744; trade name: Tarceva), the hydrochloride salt of erlotinib, is an EGFR (epidermal growth factor receptor) inhibitor with antitumor activity.

Avitinib (Abivertinib, AC-0010, AC-0010MA, AC0010, AC0010MA) is a pyrrolopyrimidine-based, orally bioactive, and irreversible/covalent inhibitor of epidermal growth factor receptor (EGFR) tyrosine kinase with selectivity against T790M resistance mutations.